

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 1 110 543 A2

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:
27.06.2001 Bulletin 2001/26

(51) Int Cl.7: **A61K 9/24, A61K 31/4545**

(21) Application number: **00311443.6**

(22) Date of filing: **20.12.2000**

(84) Designated Contracting States:
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE TR**
Designated Extension States:
AL LT LV MK RO SI

(72) Inventor: **Cho, Wing-Kee Philip**
Princeton, New Jersey 08540 (US)

(74) Representative: **Ritter, Stephen David et al**
Mathys & Squire
100 Gray's Inn Road
London WC1X 8AL (GB)

(30) Priority: **20.12.1999 US 172752 P**

(71) Applicant: **SCHERING CORPORATION**
Kenilworth, New Jersey 07033-0530 (US)

(54) **Extended release oral dosage composition**

(57) A compressed bilayer solid composition comprising (a) an immediate release first layer comprising an anti-allergic effective amount of desloratadine and at least one pharmaceutically acceptable excipient and (b)

a sustained release second layer comprising an effective amount of a nasal decongestant and a pharmaceutically acceptable sustained release agent wherein the composition contains less than about 2 % of desloratadine decomposition products is disclosed.

EP 1 110 543 A2

Description

[0001] This invention relates to a bilayer sustained release oral dosage composition containing a nasal decongestant, e.g., pseudoephedrine in one layer and the non-sedating antihistamine, desloratadine in a second layer and having less than about 2% of desloratadine degradation products. The oral dosage compositions of this invention are useful for treating patients showing the signs and symptoms associated with allergic and/or inflammatory conditions such as the common cold, as well as signs and symptoms associated with allergic and/or inflammatory conditions of the skin and airway passages such as dermatitis, allergic rhinitis, seasonal allergic rhinitis and nasal congestion, upper respiratory diseases, allergic rhinitis and nasal congestion.

[0002] Desloratadine, also called descarbethoxyloratadine, is disclosed in US Patent No. 4,659,716 as a non-sedating antihistamine useful as an anti-allergy agent. US Patent No. 5,595,997 discloses methods and compositions for treating seasonal allergic rhinitis symptoms using desloratadine.

[0003] U. S. Patent Nos. 4,990,535 and 5,100,675 disclose a twice-a-day sustained release coated tablet wherein the tablet coating comprises descarbethoxyloratadine and a hydrophilic polymer and polyethylene glycol, and the tablet core comprises acetaminophen, pseudoephedrine or a salt thereof, a swellable hydrophilic polymer and pharmaceutically acceptable excipients.

[0004] U. S. Patent No. 5,314,697 discloses an extended release tablet containing matrix core comprising pseudoephedrine sulfate and a coating comprising loratadine.

[0005] None of the prior art discloses the twice-a-day non-film-coated oral dosage composition of this invention.

[0006] The successful development of a formulation of a desloratadine-pseudoephedrine twice-a-day product would be desirable, but would require (1) achieving a release rate profile for pseudoephedrine component over an extended period of about twelve hours while maintaining the safety and effectiveness of desloratadine, and (2) minimizing impurity formation due to the interaction between desloratadine and excipients in the pseudoephedrine layer that are incompatible with desloratadine.

[0007] It would be desirable for increased patient compliance to have a stable, extended release desloratadine-pseudoephedrine product substantially free of desloratadine impurities and additional polymorphic forms that is effective and safe when used on a twice-a-day or once-a-day basis for the treatment, management and/or mitigation of the signs and symptoms associated with the common cold, as well as allergic and/or inflammatory conditions of the skin or upper and lower airway passages such as seasonal, allergic rhinitis and nasal congestion.

SUMMARY OF THE INVENTION

[0008] We have found that desloratadine discolors and decomposes in the presence of excipients disclosed in the prior art. We have discovered that these problems are substantially solved (a) when the use of an acidic excipient in the desloratadine layer is avoided and when desloratadine is combined with a pharmaceutically acceptable carrier medium comprising a desloratadine protective amount of a pharmaceutically acceptable basic salt, or (b) when a desloratadine-protective amount of a pharmaceutically acceptable antioxidant is present in at least one layer and preferably at least one of said antioxidants is present in each layer of the bilayer tablet.

[0009] Thus, this invention provides a compressed bilayer solid composition comprising (1) an immediate release first layer comprising an anti-allergic effective amount of desloratadine and a desloratadine-protective amount of a pharmaceutically acceptable water insoluble basic calcium, magnesium or aluminum salt, or of a desloratadine-protective amount of at least one pharmaceutically acceptable antioxidant; and (2) a sustained release second layer comprising an effective amount of pseudoephedrine or a salt thereof, and a pharmaceutically acceptable sustained release agent, and optionally a desloratadine-protective amount of a pharmaceutically acceptable antioxidant.

[0010] Thus, in one preferred embodiment, this invention provides a compressed bilayer solid composition comprising (1) one layer- an immediate release first layer-comprising an anti-allergic effective amount of desloratadine and desloratadine-protective amount of a pharmaceutically acceptable water insoluble basic calcium, magnesium or aluminum salt, and (2) another layer-a sustained release second layer- comprising an effective amount of pseudoephedrine or a salt thereof, and a pharmaceutically acceptable sustained release agent.

[0011] The pharmaceutical compositions of the present invention contain less than about 2.0% of desloratadine decomposition products such as N-formyl-desloratadine (see Chart I) when such compositions are stored at 25°C and about 60% relative humidity for extended time periods, e.g., about 18 months.

[0012] In a preferred embodiment, this invention provides a compressed bilayer solid composition comprising:

(a) an immediate release first layer comprising:

INGREDIENT	mg/composition
Desloratadine, micronized	2.5
Corn starch	11.0
Dibasic calcium phosphate dihydrate	53.0
Microcrystalline cellulose	30.22
Talc	3.0
FD&C Blue dye No. 2 Aluminium Lake 5627	0.28
TOTAL IN FIRST LAYER	100.00

and

(b) a second sustained release second layer comprising:

INGREDIENT	mg/composition
Pseudoephedrine Sulfate	120.0
Hydroxypropyl Methylcellulose	105.0
Microcrystalline cellulose	100.0
Povidone	18.0
Silicon Dioxide	5.0
Magnesium stearate	2.0
TOTAL IN SECOND LAYER	350.0

[0013] The above-listed preferred compressed bilayer composition contains less than about 2.0% of desloratadine decomposition products such as N-formyl-desloratadine(see Chart I) when such compositions are stored at 25°C and about 60% relative humidity for extended time periods of about 18 months.

[0014] Thus, in another preferred embodiment, the present invention also provides a compressed bilayer solid composition comprising (1) an immediate release first layer comprising an anti-allergic effective amount of desloratadine and a desloratadine-protective amount of at least one pharmaceutically acceptable antioxidant;and (2) a sustained release second layer comprising an effective amount of pseudoephedrine or a salt thereof, a pharmaceutically acceptable sustained release agent, and a desloratadine-protective amount of a pharmaceutically acceptable antioxidant. The above-listed preferred compressed bilayer composition contains less than about 2.0% of desloratadine decomposition products such as N-formyl-desloratadine (see Chart I) when such compositions are stored at 25°C and about 60% relative humidity for extended time periods of about 18 months.

[0015] The present invention provides a compressed bilayer solid composition comprising (a) an immediate release first layer comprising an anti-allergic effective amount of desloratadine and at least one pharmaceutically acceptable excipient and (b) a sustained release second layer comprising an effective amount of a nasal decongestant and a pharmaceutically acceptable sustained release agent. In a preferred embodiment, the compressed bilayer solid composition contains less than about 2.0% of desloratadine decomposition products such as N-formyl desloratadine after storage for about 18 months, and wherein at least about 80% of the desloratadine dissolves in 0.1N HCl at 37°C in about 45 minutes.

[0016] In another preferred embodiment, the present invention also provides a compressed bilayer solid composition comprising (1) an immediate release first layer comprising 5 mg of desloratadine and desloratadine-protective amount of a pharmaceutically acceptable water insoluble basic calcium, magnesium or aluminum salt, and (2) a sustained release second layer comprising 120 mg of pseudoephedrine sulfate, and a pharmaceutically acceptable sustained release agent. This preferred composition provides a 24-hr dose of desloratadine and a 12-hr dose of pseudoephedrine sulfate.

[0017] Thus, the present invention also provides a method of treating and/or preventing allergic and inflammatory conditions of the upper and lower airway passages and skin which comprises administering to a patient in need of such treating an effective amount of a compressed bilayer solid composition of the present invention.

DETAILED DESCRIPTION OF THE INVENTION

[0018] During the course of development of the compositions of the present invention, desloratadine was found to

be unstable and to discolor when stored in combination with various excipients such as those disclosed in U.S. Patent No. 5,314,697 as part of the matrix core containing pseudoephedrine sulfate. The excipients causing discoloration and instability of desloratadine include acidic excipients having a pH of less than 7 in water such as organic acids, such as stearic acid, povidone, crospovidone as well as the hydroxycarboxylic acid, ascorbic acid, and carbonyl-containing materials such as lactose, and ethylcellulose and hydroxypropyl methylcellulose. Binders like povidone and polymers such as hydroxypropyl methylcellulose are useful as a polymer matrix for the sustained release of the pseudoephedrine sulfate from the inner polymer matrix core.

[0019] We also discovered that metal ions catalyzed were involved in the formation of desloratadine degradation products.

[0020] We have discovered two solutions to inhibit and/or prevent formation of desloratadine degradation products. In one preferred embodiment, a desloratadine-protective amount of a pharmaceutically acceptable anti-oxidant should be present in at least one of the bilayers, preferably one of said antioxidant in each layer.

[0021] In a second preferred embodiment, we also discovered that it is possible to prepare a bilayer tablet containing desloratadine in an immediate release first layer in intimate contact with a sustained release second layer containing a nasal decongestant and excipients incompatible with desloratadine by incorporating a desloratadine protective amount of a pharmaceutically acceptable water insoluble basic calcium, magnesium or aluminum salt into the immediate release desloratadine layer.

[0022] The term "in intimate contact" as used herein in reference to the two layer forming the bilayer tablet means that there is with no film interface between the two layers.

[0023] The term "pharmaceutically acceptable antioxidant" as used herein in reference to desloratadine (formula I in the Chart) means a pharmaceutically acceptable chelating agent that protects desloratadine from the formation of degradation products including, but not limited to those of the formulas II-V listed in the Chart ,e.g.,N-formyl-desloratadine or N-formyl DL(formula II in the Chart), N-hydroxylamine of DL (formula V in the Chart) N-oxide of DL(formula IV in the Chart), and the 3'-hydroxyl N-oxide of DL(formula III in the Chart). The structures listed in the Chart were determined by standard physicochemical techniques,e.g.,LC-MS, and LC-NMR.

[0024] Typically suitable pharmaceutically acceptable antioxidants for DL are pharmaceutically acceptable chelating agents such as those disclosed in "Chelating Agents", pages 764-794, Vol. 5 of KIRTH-OTHMER, ENCYCLOPEDIA OF CHEMICAL TECHNOLOGY, 4th Edition, 1993, John Wiley & Sons Inc., NY, and preferably including, but not limited to, hydroxycarboxylic acids, such as tartaric acid, citric acid and gluconic acid, and pharmaceutically acceptable salts thereof, aminocarboxylic acids such as edetic acid (ethylenediamine tetraacetic acid) and pharmaceutically acceptable salts thereof such as edetate calcium disodium, edetate disodium, edetate trisodium, and edetate tetrasodium. Edetate disodium and citric acid are the preferred pharmaceutically acceptable antioxidants. Use of the hydroxycarboxylic acid, ascorbic acid, is to be avoided

[0025] The desloratadine protective amount of a pharmaceutically acceptable antioxidant in the DL immediate release layer is in the range of about 0.1% to about 10% by weight, preferably about 1% to 8% or about 1% to about 6%, more preferably about 4% to about 8%, or about 4% to about 6%, or most preferably about 5% to about 6%. The desloratadine protective amount of a pharmaceutically acceptable antioxidant in the PES sustained release layer is in the range of 0% to about 10%, preferably about 0.1% to about 10%, or about 0.1% to about 3%, more preferably about 1 to about 2%, and most more preferably about 1.0%. In a preferred embodiment of the present invention, about 1.0% by weight of a pharmaceutically acceptable antioxidant, e.g., edetate disodium, is present in the PES sustained release layer. In another preferred embodiment, about 6% by weight of a mixture of two pharmaceutically acceptable antioxidants, e.g., edetate disodium and citric acid, are present in the DL immediate release layer in a ratio of about 5:1 to about 1:5, preferably about 5:1, and about 1% of a pharmaceutically acceptable antioxidant, e.g., edetate disodium, is present in the sustained release layer. In another preferred embodiment, about 5% by weight of one pharmaceutically acceptable antioxidant, e.g., edetate disodium, is present in the DL immediate release layer.

[0026] In other preferred embodiments, about 5.0 mg (a 24-hour supply) of DL is present in the DL immediate release layer, and 120 mg (a 12-hour supply) of the nasal decongestant pseudoephedrine sulfate is present in the sustained release layer(see Examples 4,5&6). In one preferred embodiment, the dibasic phosphate salt preferably dibasic calcium phosphate dihydrate is present in the DL immediate release layer and no pharmaceutically acceptable antioxidant is present in either layer (see Example 4). In another preferred embodiment, 5.0 mg (a 24-hour supply) of DL and about 0.1 to about 10% of at least one antioxidant is present in the DL immediate release layer, preferably about 4% to about 6% of a mixture of two antioxidants, e.g.,edetate disodium and citric acid, in a ratio of 5:1 to 1:1, preferably in a ratio of 5:1, and about 0.1% to about 10% preferably about 0.1% to about 5%, more preferably about 0.1% to about 3%, most more preferably about 1.0% of an antioxidant, e.g.,edetate disodium, is present in the PES sustained release layer(see Examples 5&6).

[0027] The desloratadine was found to have an acceptable immediate release profile from the second layer (80% release in 0.1N HCl in less than about 45 min.) and contain less than about 2% of desloratadine degradation products even after storage for at least 18 months at 25° C and about 60% relative humidity ("RH").

[0028] The phrase "allergic and inflammatory conditions of the skin and airway passages" means those allergic and inflammatory conditions and symptoms found on the skin and in the upper and lower airway passages from the nose to the lungs. Typical allergic and inflammatory conditions of the skin and upper and lower airway passages include seasonal and perennial allergic rhinitis, non-allergic rhinitis, asthma including allergic and non-allergic asthma, sinusitis, colds (in combination with a NSAID, e.g., aspirin ibuprofen or APAP) and/or a decongestant e.g. pseudoephedrine), dermatitis, especially allergic and atopic dermatitis, and urticaria and symptomatic dermatographism as well as retinopathy, and small vessel diseases, associated with diabetes mellitus.

[0029] The amount of desloratadine effective for treating or preventing allergic and inflammatory conditions of the skin and upper and lower airway passages will vary with the age, sex, body weight and severity of the allergic and inflammatory condition of the patient. Typically, the amount of desloratadine effective for treating or preventing such allergic and inflammatory conditions is in the range of about 2.5 mg/day to about 60 mg/day, preferably about 2.5 mg/day to about 20 mg/day, or about 4.0 mg/day to about 15 mg/day, or about 5.0 mg/day to about 10 mg/day, more preferably about 5.0 mg/day to about 10.0 mg/day, and most preferably about 5.0 mg/day in one dose or in two divided doses of 2.5 mg/dose.

[0030] Desloratadine is a non-sedating long acting histamine antagonist with potent selective peripheral H₁-receptor antagonist activity. Following oral administration, loratadine is rapidly metabolized to descarboethoxyloratadine or desloratadine, a pharmacologically active metabolite. *In vitro* and *in vivo* animal pharmacology studies have been conducted to assess various pharmacodynamic effects of desloratadine and loratadine. In assessing antihistamine activity in mice (comparison of ED₅₀ value), desloratadine was relatively free of producing alterations in behavior alterations in behavior, neurologic or autonomic function. The potential for desloratadine or loratadine to occupy brain H₁-receptors was assessed in guinea pigs following i.p. administration and results suggest poor access to central histamine receptors for desloratadine or loratadine.

[0031] In addition to antihistaminic activity, desloratadine has demonstrated anti-allergic and anti-inflammatory activity from numerous *in vitro* and *in vivo* tests. These *in vitro* tests (mainly conducted on cells of human origin) have shown that desloratadine can inhibit many events in the cascade of allergic inflammation. These anti-inflammatory effects for desloratadine are independent of the H₁-antagonist effect of desloratadine and include:

- The release of inflammatory mediators histamine, trypsin, leukotriene and prostaglandin D₂ from mast cells;
- The release of inflammatory cytokines including IL-4, IL-6, IL-8 and IL-13;
- The release of the inflammatory chemokines such as RANTES (regulated upon activation, normal T cell expressed and presumably secreted);
- Superoxide anion production of polymorphonuclear neutrophils;
- The expression of cell adhesion molecules such as intracellular adhesion molecules (ICAM-1) and P-selectin in endothelial cells; and
- Eosinophil migration and adhesion

In vivo studies also suggest that an inhibitory effect of desloratadine on allergic bronchospasm and cough can also be expected.

[0032] The clinical efficacy and safety of desloratadine has been documented in over 3,200 seasonal allergic rhinitis patients in 4 double-blind, randomized clinical trials. The results of these chemical studies demonstrated the efficacy of desloratadine in the treatment of adult and adolescent patients with seasonal rhinitis.

[0033] The nasal decongestants useful in the present invention include phenylpropanolamine, phenylephrine and pseudoephedrine. Pseudoephedrine as well as pharmaceutically acceptable acid additional salts, e.g., those of HCl or H₂SO₄, is a sympathomimetic drug recognized by those skilled in the art as a safe therapeutic agent effective for treating nasal congestion and is commonly administered orally and concomitantly with an antihistamine for treatment of nasal congestion associated with allergic rhinitis. The use of pseudoephedrine as a nasal decongestant in the present invention is preferred; the use of about 120 mg pseudoephedrine sulfate in the extended release layer is more preferred.

[0034] In the course of development of the compressed bilayer oral dosage composition of this invention, it was discovered that the selection of the polymers for the extended release layer was critical to achieve the desired extended release period of at least 12 hours, for pseudoephedrine sulfate. For example, the use of hydroxypropyl methylcellulose 4,000 cps or 15,000 cps as polymers in the matrix core did not provide this more preferred extended release period of at least 16 hours for dose of pseudoephedrine sulfate. We discovered that only by selecting for inclusion into the matrix core of specific weight ratios of three specific polymers was the desired pseudoephedrine release profile achieved. Only by combining (1) about one part by weight, preferably 1.05 parts by weight of hydroxypropyl methylcellulose 2208 USP, 100,000 cps with (2) about one part by weight, preferably 1.0 parts by weight of microcrystalline cellulose together with (3) about 0.15-0.20 part by weight, preferably 0.17-0.18 parts by weight of povidone (per 1.05 parts by weight of hydroxypropyl methylcellulose) as a secondary binder was the more preferred extended release profile of at least 12 hours for pseudoephedrine sulfate from the extended release layer. The extended release layer

also contains specific amounts of silicon dioxide as a glidant and magnesium stearate as a lubricant. The tablet hardness 20 ± 4 Strong-Cobb Units (SCU) is not greatly affected by the higher level of lubricant (6mg/tablet) but it is preferred to maintain the lubricant level at 1/9 part by weight of lubricant to one part by weight of povidone as secondary binder.

[0035] The term "lubricant" as used herein refers to a substance added to the dosage form to enable the dosage form, e.g., a tablet, after it has been compressed to release from the mold or die.

[0036] Suitable lubricants include talc, magnesium stearate, calcium stearate, stearic acid, hydrogenated vegetable oils and the like. Preferably, magnesium stearate or talc is used.

[0037] The term "glidants" as used herein refers to a substance, such as an anti-caking agent, which improves the flow characteristics of a powder mixture.

[0038] Suitable glidants include silicon dioxide and talc. Preferably, silicon dioxide is used.

[0039] The term "binders" as used herein means any material that is added to pharmaceutical compositions to help hold such compositions together and release the medicament therefrom.

[0040] Suitable binders are selected those found in NF XVIII, page 2206 (1995) and include povidones, starches, celluloses, alginates, and gums and low molecular weight hydroxypropyl methyl celluloses, especially hydroxypropyl methyl cellulose 2910.

[0041] The term "pharmaceutically acceptable water insoluble basic calcium, magnesium and aluminium salts" as used herein means the pharmaceutically acceptable carbonates, phosphates, silicates and sulfates of calcium, magnesium and aluminum or mixtures thereof. Typically suitable pharmaceutically acceptable basic salts include calcium sulfate anhydrous, hydrates of calcium sulfate, such as calcium sulfate dihydrate, magnesium sulfate anhydrous, hydrates of magnesium sulfate, dibasic calcium phosphate, dibasic calcium silicate, magnesium trisilicate, magnesium phosphate, aluminum silicate, and hydrates of magnesium phosphate, aluminum phosphate; and calcium phosphate is more preferred. The use of dibasic calcium phosphate dihydrate is most preferred.

[0042] The desloratadine-protective amount of a pharmaceutically acceptable water insoluble basic calcium, magnesium or aluminum salt is in the range of about 50-60% of the DL immediate release layer, and the w/w ratio of the pharmaceutically acceptable water insoluble basic calcium, magnesium or aluminum salt to DL is in the range of about 8:1 to about 40:1, more preferably is in the range of about 10:1 to about 20:1, and most preferably is in the range of about 10:1 to about 11:1.

[0043] In the preferred embodiment of the present invention wherein a desloratadine protective amount of a pharmaceutically acceptable antioxidant is present, the water insoluble basic calcium salt is not present in the immediate release layer containing desloratadine; in its place, at least one, preferably two pharmaceutically acceptable antioxidants are present, e.g., edetate sodium and citric acid and the amount of microcrystalline cellulose is increased. In addition, when the pharmaceutically acceptable antioxidant is used in place of the water insoluble basic calcium, magnesium or aluminum salt, the povidone in the sustained release layer is replaced by another binder, preferably a low molecular weight hydroxypropyl methyl cellulose ("HPMC"), preferably HPMC 2910.

[0044] The oral dosage composition of this invention also provides a shelf life of up to 18 months so long as the tablets are stored in standard package at between 2° and 30° C in an ambient environment of 60% relative humidity.

[0045] In the preparation of the bilayer tablet, the sustained release layer is compacted first. The immediate release second layer is added on top and a compression force sufficient to form a bilayer tablet is applied in the range of 8-12 kilo Newtons, preferably about 9 kilo Newtons(kN).

[0046] The dried sustained release granulation is milled and blended with requisite amounts of silicon dioxide and magnesium stearate. In a preferred embodiment, a pharmaceutically acceptable blue dye containing EDTA as a chelating agent is incorporated into the immediate release desloratadine layer. Use of a pharmaceutically acceptable blue dye, e.g. FD& C blue dye No. 2 Aluminum Lake 5627 is preferred.

EXAMPLE I

[0047] This example illustrates preparation of the preferred oral dosage composition of this invention. The ingredients and specific amounts thereof are listed below.

A. Method of Manufacture of the Immediate Release Layer

[0048]

1. Prepare starch paste by dispersing the paste portion of corn starch into purified water in a suitable container equipped with an agitator.

2. While mixing, heat the contents to approximately 95°C and maintain the temperature for approximately 30 minutes.

EP 1 110 543 A2

3. After Step 2 is completed, add an additional purified water and allow the starch paste to cool to approximately 50°C.

4. While mixing, add desloratadine to the starch paste. Continue mixing during the granulation step.

5. Pass the FD&C blue No. 2 aluminum lake containing EDTA as a chelating, e.g., Spectra Spray Med Blue, with the required amount of dibasic calcium phosphate through a suitable sieve or mill.

6. Charge to a suitable fluid bed processing bowl the remaining dibasic calcium phosphate dihydrate, the milled material from Step 5, a portion of the corn starch, and a portion of microcrystalline cellulose. Place the processing bowl into the fluid bed processor.

7. Fluidize the powder bed until the product temperature reaches approximately 29°C.

8. Begin granulating the powder by pumping the starch paste from Step 4 into the fluidized bed at a suitable spray rate and a bed temperature of approximately 22°C.

9. Continue to dry the granulation at an inlet air temperature of approximately 60°C until a final loss on drying (LOD) of 2% or less is achieved.

10. Pass the dried granulation through a suitable sieve or mill.

11. Charge the granulation to a suitable blender and add the requisite amounts of the remaining portion of microcrystalline cellulose, corn starch, and talc. Blend for 5 minutes.

B. Manufacture of Sustained Release Mix:

[0049]

1. Charge purified water and alcohol to a suitable container equipped with an agitator.

2. Dissolve povidone in the water/alcohol mixture. Continue mixing for a minimum of 10 minutes.

3. Mix hydroxypropyl methylcellulose, pseudoephedrine sulfate and microcrystalline cellulose in a suitable granulator.

4. Granulate the mix with the povidone solution, using additional water/alcohol mixture if necessary to achieve the appropriate granulation consistency.

5. Dry the wet granulation at approximately 50°C in a suitable dryer until the loss on drying (LOD) is between 1% and 3%.

6. Pass the dried granulation through a suitable sieve or mill.

7. Charge the milled granulation to a suitable blender.

8. Pass the silicon dioxide through a No. 30 mesh screen into the blender.

9. Blend the requisite amount of screened silicon dioxide with the granulation for approximately 10 minutes in a suitable blender.

10. Pass the magnesium stearate through a No. 30 mesh screen.

11. Blend the requisite amount of screened magnesium stearate with the mix from Step 9 for 5 minutes.

C. Compression:

[0050] Compress the two blends to specifications as bilayer tablets using a suitable double-layer tablet press using

EP 1 110 543 A2

a compression force of 9k Newtons. Compress the sustained release layer first.

- Tablet Weight: 450 mg± 5%
- Sustained release layer: 350 mg± 5%
- Immediate release layer: 100 mg ± 5%
- Hardness: 20 ± 4 SCU (Strong Cobb units)

[0051] The following bilayer tablet was prepared using the above procedure.

Desloratadine Immediate Release Layer:	
INGREDIENT	mg/composition
Desloratadine, micronized	2.5
Corn Starch NF/Ph.Eur.	11.0
Dibasic Calcium Phosphate Dihydrate USP/Ph.Eur.	53.0
Microcrystalline Cellulose NF/Ph.Eur./JP	30.22
Talc USP/Ph.Eur.	3.0
Dye FD&C Blue No. 2 Aluminium Lake 5627	0.28
Water Purified USP/Ph.Eur.	-----
TOTAL	100.00

and

Pseudoephedrine Sulfate Sustained Release Layer	
INGREDIENT	mg/composition
Pseudoephedrine Sulfate USP	120.0
Hydroxypropyl Methylcellulose USP/Ph.Eur.	105.0
Microcrystalline Cellulose 2208, 100,000cpsNF/Ph.Eur./JP	100.0
Povidone USP/Ph.Eur./JP	18.0
Silicon Dioxide NF	5.0
Magnesium Stearate NF/Ph.Eur.JP(Non-Bovine)	2.0
Water Purified USP/Ph.Eur.	----
Alcohol USP/3A Alcohol	----
TOTAL	350.0
TOTAL TABLET	450.0

Hardness: 20 ± 4 SCU (Strong Cobb units)

EXAMPLE 2

[0052] The procedure of Example 1 was used; edetate disodium was used in place of the dibasic calcium salt and the amount of microcrystalline cellulose in the DL layer was increased. Edetate disodium was used in the sustained release layer and hydroxypropyl methylcellulose 2910 was used in place of povidone.

Desloratadine Immediate Release Layer:	
INGREDIENT	mg/composition
Desloratadine, micronized	2.5
Corn Starch NF/Ph.Eur.	8.0
Microcrystalline Cellulose NF/Ph.Eur./JP	71.35
Edetate Disodium	5.0

EP 1 110 543 A2

(continued)

Desloratadine Immediate Release Layer:	
INGREDIENT	mg/composition
Talc USP/Ph.Eur.	3.0
Dye FD&C Blue No. 2 Aluminium Lake 5627	0.15
Water Purified USP/Ph.Eur.	-----
TOTAL	100.00

and

Pseudoephedrine Sulfate Sustained Release Layer	
INGREDIENT	mg/composition
Pseudoephedrine Sulfate USP	120.0
Hydroxypropyl Methylcellulose 2208, USP/Ph.Eur.	105.0
Microcrystalline Cellulose NF/Ph.Eur./JP	103.5
Edetate Disodium	3.5
Hydroxypropyl Methylcellulose 2910 USP/Ph.Eur./JP	10.5
Silicon Dioxide NF	5.0
Magnesium Stearate NF/Ph.Eur.JP(Non-Bovine)	2.5
Water Purified USP/Ph.Eur.	-----
Alcohol USP/3A Alcohol	-----
TOTAL	350.0
TOTAL TABLET	450.0

Hardness: 20 ± 4 SCU (Strong Cobb units)

EXAMPLE 3

[0053] The procedure of Example 2 was used, but 1 mg of citric acid was added to the DL layer and the amount of microcrystalline cellulose was decreased by 1 mg.

Desloratadine Immediate Release Layer:	
INGREDIENT	mg/composition
Desloratadine, micronized	2.5
Corn Starch NF/Ph.Eur.	18.0
Edetate Disodium	5.0
Citric Acid	1.0
Microcrystalline Cellulose NF/Ph.Eur./JP	70.35
Talc USP/Ph.Eur.	3.0
Dye FD&C Blue No. 2 Aluminium Lake 5627	0.15
Water Purified USP/Ph.Eur.	-----
TOTAL	100.00

And Pseudoephedrine Sulfate Sustained Release Layer	
INGREDIENT	mg/composition
Pseudoephedrine Sulfate USP	120.0
Hydroxypropyl Methylcellulose 2208, 100,000cps USP/Ph.Eur.	105.0
Microcrystalline Cellulose NF/Ph.Eur./JP	103.5

EP 1 110 543 A2

(continued)

And Pseudoephedrine Sulfate Sustained Release Layer	
INGREDIENT	mg/composition
Edetate Disodium	3.5
Hydroxypropyl Methylcellulose 2910	10.5
Silicon Dioxide NF	5.0
Magnesium Stearate NF/Ph.Eur.JP(Non-Bovine)	2.5
Water Purified USP/Ph.Eur.	----
Alcohol USP/3A Alcohol	----
TOTAL	350.0
TOTAL TABLET	450.0

Hardness: 20 ± 4 SCU (Strong Cobb units)

EXAMPLE 4

[0054] The procedure of Example 1 was used. The bilayer tablet of Example 1 was modified by including 5.0 mg of desloratadine in the immediate release layer-(a 24 hour dose)-with the appropriate changes in amounts of the other ingredients and using the 12-hr dose pseudoephedrine sustained release layer of Example 1. Hardness:20 ± 4 SCU (Strong Cobb units)

Desloratadine Immediate Release Layer:	
INGREDIENT	mg/composition
Desloratadine, micronized	5.0
Corn Starch NF/Ph.Eur.	11.0
Dibasic Calcium Phosphate Dihydrate USP/Ph.Eur.	53.0
Microcrystalline Cellulose NF/Ph.Eur./JP	27.72
Talc USP/Ph.Eur.	3.0
Dye FD&C Blue No. 2 Aluminium Lake 5627	0.28
Water Purified USP/Ph.Eur.	----
TOTAL	100.00

and

Pseudoephedrine Sulfate Sustained Release Layer	
INGREDIENT	mg/composition
Pseudoephedrine Sulfate USP	120.0
Hydroxypropyl Methylcellulose 2208,1000,00cps USP/Ph.Eur.	105.0
Microcrystalline Cellulose NF/Ph.Eur./JP	100.0
Povidone USP/Ph.Eur./JP	18.0
Silicon Dioxide NF	5.0
Magnesium Stearate NF/Ph.Eur.JP(Non-Bovine)	2.0
Water Purified USP/Ph.Eur.	----
Alcohol USP/3A Alcohol	----
TOTAL	350.0
TOTAL TABLET	450.0

EXAMPLE 5

[0055] The procedure of Example 1 was used and the bilayer tablet of Example 4 was modified by replacing the

EP 1 110 543 A2

dibasic calcium phosphate dihydrate in the immediate release layer with 10 mg of edetate disodium and increasing the amount of microcrystalline cellulose by 2.7 mg. Hardness: 20 ± 4 SCU (Strong Cobb units)

Desloratadine Immediate Release Layer:	
INGREDIENT	mg/composition
Desloratadine, micronized	5.0
Corn Starch NF/Ph.Eur.	36.0
Microcrystalline Cellulose NF/Ph.Eur./JP	142.7
Edetate Disodium	10.0
Talc USP/Ph.Eur.	6.0
Dye FD&C Blue No. 2 Aluminium Lake 5627	0.30
Water Purified USP/Ph.Eur.	-----
TOTAL	200.00

and

Pseudoephedrine Sulfate Sustained Release Layer	
INGREDIENT	mg/composition
Pseudoephedrine Sulfate USP	120.0
Hydroxypropyl Methylcellulose 2208,1000,00cps USP/Ph.Eur.	105.0
Microcrystalline Cellulose NF/Ph.Eur./JP	103.5
Hydroxypropyl Methylcellulose 2910	10.5
Edetate Disodium	3.5
Silicon Dioxide NF	5.0
Magnesium Stearate NF/Ph.Eur.JP(Non-Bovine)	2.5
Water Purified USP/Ph.Eur.	----
Alcohol USP/3A Alcohol	----
TOTAL	350.0
TOTAL Tablet Weight	550.0

EXAMPLE 6

[0056] The bilayer tablet of Example 5 was modified by adding 2.0 mg of citric acid to the immediate release layer and decreasing the amount of microcrystalline cellulose by 2.7 mg and using the pseudoephedrine sustained release layer of Example 1. Hardness: 20 ± 4 SCU (Strong Cobb units)

Desloratadine Immediate Release Layer:	
INGREDIENT	mg/composition
Desloratadine, micronized	5.0
Corn Starch NF/Ph.Eur.	36.0
Microcrystalline Cellulose NF/Ph.Eur./JP	140.7
Edetate Disodium	10.0
Citric Acid	2.0
Talc USP/Ph.Eur.	6.0
Dye FD&C Blue No. 2 Aluminium Lake 5627	0.30
Water Purified USP/Ph.Eur.	-----
TOTAL	200.00

And <u>Pseudoephedrine Sulfate Sustained Release Layer</u>		
	<u>INGREDIENT</u>	<u>mg/composition</u>
5	Pseudoephedrine Sulfate USP	120.0
	Hydroxypropyl Methylcellulose 2208,1000,00cps USP/Ph.Eur.	105.0
	Microcrystalline Cellulose NF/Ph.Eur./JP	103.5
	Hydroxypropyl Methylcellulose 2910	10.5
10	Edetate Disodium	3.5
	Silicon Dioxide NF	5.0
	Magnesium Stearate NF/Ph.Eur.JP(Non-Bovine)	2.5
	Water Purified USP/Ph.Eur.	----
	Alcohol USP/3A Alcohol	----
15	TOTAL	<u>350.0</u>
	TOTAL Tablet Weight	550.0

[0057] The *in vitro* dissolution profile of the tablets of Examples 1-6 were measured in a stirred 0.1N HCl solution at 37°C (1st hour) and thereafter in a stirred phosphate buffer having a pH of 7.5 at 37°C. The 80% of desloratadine in the immediate release layers was dissolved within the first 30 minutes and the total dose of pseudoephedrine sulfate in the sustained release layers was slowly released via erosion and dissolution mechanisms over a period of at least 12 hours. (with 30-45% in 1 hr, 50-60% in 2 hrs. and ≥80% in 6 hrs).


[0058] Similar results would be expected if a decongestant effective amount of another pharmaceutically acceptable pseudoephedrine salt, e.g., pseudoephedrine hydrochloride was used in place of pseudoephedrine sulfate.

[0059] The compositions of the present invention are useful for treatment of allergic and/or inflammatory conditions of the skin (e.g. urticaria) and the upper and lower airway passages including the nasal and non-nasal symptoms of seasonal allergic rhinitis including nasal congestion in a patient in need of such treating. The precise dosage and dosage regimen may be varied by the attending clinician in view of the teachings herein depending upon the requirements of the patient, e.g., the patient's age, sex and the severity of the allergic and/or inflammatory condition being treated. Determination of the proper dosage and dosage regimen for a particular patient will be within the skill of the attending clinician.


While we have hereinabove presented a number of preferred embodiments of this invention by way of example, it is apparent that the scope of the invention is to be defined by the scope of the appended claims.

CHART

[0060]




I




III

II



IV



V

Claims

1. A compressed bilayer solid composition comprising (1) a first layer comprising an anti-allergic effective amount of desloratadine and a desloratadine-protective amount of a pharmaceutically acceptable water insoluble basic calcium, magnesium or aluminum salt, or of a desloratadine-protective amount of at least one pharmaceutically acceptable antioxidant; and (2) a second layer comprising an effective amount of pseudoephedrine or a salt thereof, and a pharmaceutically acceptable excipient, and optionally a desloratadine-protective amount of a pharmaceutically acceptable antioxidant.
2. A compressed bilayer solid composition according to Claim 1 comprising (1) a first layer comprising an anti-allergic effective amount of desloratadine and a desloratadine-protective amount of at least one pharmaceutically acceptable antioxidant; and (2) a second layer comprising an effective amount of pseudoephedrine or a salt thereof, a pharmaceutically acceptable excipient, and a desloratadine-protective amount of a pharmaceutically acceptable antioxidant.
3. A compressed bilayer solid composition according to Claim 1 comprising (1) a first layer comprising an anti-allergic effective amount of desloratadine and desloratadine-protective amount of a pharmaceutically acceptable water insoluble basic calcium, magnesium or aluminum salt, and (2) a second layer comprising an effective amount of pseudoephedrine or a salt thereof.
4. A compressed bilayer solid composition comprising (a) an immediate release first layer comprising an anti-allergic

effective amount of desloratadine and at least one pharmaceutically acceptable excipient and (b) a sustained release second layer comprising an effective amount of a nasal decongestant and a pharmaceutically acceptable excipient, wherein the total amount of desloratadine degradation products is less than about 2%.

- 5 5. The compressed bilayer solid composition of claim 4 wherein the nasal decongestant is pseudoephedrine, or a pharmaceutically acceptable salt thereof.
- 10 6. The compressed bilayer solid composition of any preceding claim wherein the first layer is an immediate layer and wherein the second layer is a sustained release layer containing a pharmaceutically acceptable sustained release agent.
- 15 7. The compressed bilayer solid composition of any preceding claim wherein at least about 80% of the desloratadine dissolves in a 0.1 N HCl solution at 37°C in about 45 minutes.
- 15 8. The compressed bilayer solid composition of any preceding claim wherein the amount of N-formyl-desloratadine is less than about 0.5% after storage at 25°C and 60% relative humidity for an extended time period.
- 20 9. The compressed bilayer solid composition of claim 1 or 2 wherein about 0.1 % to about 10% of a pharmaceutically acceptable antioxidant is present in each layer.
- 20 10. The compressed bilayer solid composition of any preceding claim wherein the anti-allergic effective amount of desloratadine in the first layer is about 2.5 mg.
- 25 11. The compressed bilayer solid composition of any preceding claim wherein the anti-allergic effective amount of desloratadine in the first layer is about 5.0 mg.
- 25 12. The compressed bilayer solid composition of claim 1 or 2 wherein two pharmaceutically acceptable antioxidants are present in the desloratadine layer.
- 30 13. The compressed bilayer solid composition of claim 1 or 3 wherein an immediate release first layer comprises:

<u>INGREDIENT</u>	<u>mg/composition</u>
Desloratadine, micronized	2.5
Corn Starch	11.0
Dibasic Calcium Phosphate Dihydrate	53.0
Microcrystalline Cellulose	30.22
Talc	3.0
Dye FD+C Blue No. 2 Aluminium Lake	0.28
TOTAL	<u>100.00</u>

and

and wherein an sustained release layer comprises

<u>INGREDIENT</u>	<u>mg/composition</u>
Pseudoephedrine Sulfate	120.0
Hydroxypropyl Methylcellulose	105.0
Microcrystalline cellulose	100.0
Povidone	18.0
Silicon Dioxide	5.0
Magnesium stearate	2.0
TOTAL	<u>350.0</u>

14. The compressed bilayer solid composition of claim 1 or 3 wherein an immediate release first layer comprises:

<u>INGREDIENT</u>	<u>mg/composition</u>
Desloratadine, micronized	2.5
Corn Starch	18.0
Microcrystalline Cellulose	70.35-71.35
Edetate Disodium	5.0
Citric Acid	0-1.0
Talc	3.0
Dye FD+C Blue No. 2 Aluminium Lake	0.28
TOTAL	100.00

and

and wherein an sustained release layer comprises:

<u>INGREDIENT</u>	<u>mg/composition</u>
Pseudoephedrine Sulfate	120.0
Hydroxypropyl Methylcellulose 2208	105.0
Microcrystalline cellulose	103.5
Edetate Disodium	3.5
Hydroxypropyl Methylcellulose 2910	10.5
Silicon Dioxide	5.0
Magnesium stearate	2.0
TOTAL	350.0

15. A compressed bilayer solid composition according to Claim 3 comprising (1) a first layer comprising 2.5 or 5.0 mg of desloratadine and desloratadine-protective amount of a pharmaceutically acceptable water insoluble basic calcium, magnesium or aluminum salt; and (2) a second layer comprising 120 mg of pseudoephedrine or a salt thereof, and a pharmaceutically acceptable excipient.
16. A compressed bilayer solid composition according to Claim 2 comprising (1) a first layer comprising 2.5 mg or 5.0 mg of desloratadine and a desloratadine-protective amount of at least one pharmaceutically acceptable antioxidant; and (2) a second layer comprising 120 mg of pseudoephedrine or a salt thereof, a pharmaceutically acceptable excipient, and a desloratadine-protective amount of a pharmaceutically acceptable antioxidant.
17. The compressed bilayer solid composition of claim 15 or 16 wherein the amount of desloratadine in the first layer is about 2.5 mg.
18. The compressed bilayer solid composition of Claim 15 or 16 wherein the amount of desloratadine in the first layer is about 5.0 mg.
19. The compressed bilayer solid composition of claim 1 or 3 wherein the immediate release first layer comprises:

<u>Desloratadine Immediate Release Layer:</u>	
<u>INGREDIENT</u>	<u>mg/composition</u>
Desloratadine, micronized	5.0
Corn Starch NF/Ph.Eur.	11.0
Dibasic Calcium Phosphate Dihydrate USP/Ph.Eur.	53.0
Microcrystalline Cellulose NF/Ph.Eur./JP	27.72
Talc USP/Ph.Eur.	3.0
Dye FD&C Blue No. 2 Aluminium Lake 5627	0.28
Water Purified USP/Ph.Eur.	-----
TOTAL	100.00

and

Pseudoephedrine Sulfate Sustained Release Layer	
INGREDIENT	mg/composition
Pseudoephedrine Sulfate USP	120.0
Hydroxypropyl Methylcellulose 2208,1000,00cps USP/Ph.Eur.	105.0
Microcrystalline Cellulose NF/Ph.Eur./JP	100.0
Povidone USP/Ph.Eur./JP	18.0
Silicon Dioxide NF	5.0
Magnesium Stearate NF/Ph.Eur.JP(Non-Bovine)	2.0
Water Purified USP/Ph.Eur.	----
Alcohol USP/3A Alcohol	----
TOTAL	350.0
TOTAL TABLET	450.0

20. The compressed bilayer solid composition of claim 1 or 2 wherein an immediate release first layer comprises:

Desloratadine Immediate Release Layer:	
INGREDIENT	mg/composition
Desloratadine, micronized	5.0
Corn Starch NF/Ph.Eur.	36.0
Microcrystalline Cellulose NF/Ph.Eur./JP	140.7-142.7
Edetate Disodium	10.0
Citric Acid	0-2.0
Talc USP/Ph.Eur.	6.0
Dye FD&C Blue No. 2 Aluminium Lake 5627	0.30
Water Purified USP/Ph.Eur.	----
TOTAL	200.00

And

Pseudoephedrine Sulfate Sustained Release Layer	
INGREDIENT	mg/composition
Pseudoephedrine Sulfate USP	120.0
Hydroxypropyl Methylcellulose 2208,1000,00cps USP/Ph.Eur.	105.0
Microcrystalline Cellulose NF/Ph.Eur./JP	103.5
Hydroxypropyl Methylcellulose 2910	10.5
Edetate Disodium	3.5
Silicon Dioxide NF	5.0
Magnesium Stearate NF/Ph.Eur.JP(Non-Bovine)	2.5
Water Purified USP/Ph.Eur.	----
Alcohol USP/3A Alcohol	----
TOTAL	350.0
TOTAL Tablet Weight	550.0

21. The compressed bilayer solid composition of any preceding claim wherein the total amount of desloratadine degradation products is less than about 2%.

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 1 110 543 A3

(12)

EUROPEAN PATENT APPLICATION

(88) Date of publication A3:
29.08.2001 Bulletin 2001/35

(51) Int Cl.7: **A61K 9/24, A61K 31/4545**

(43) Date of publication A2:
27.06.2001 Bulletin 2001/26

(21) Application number: **00311443.6**

(22) Date of filing: **20.12.2000**

(84) Designated Contracting States:
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE TR**
Designated Extension States:
AL LT LV MK RO SI

(30) Priority: **20.12.1999 US 172752 P**

(71) Applicant: **SCHERING CORPORATION**
Kenilworth, New Jersey 07033-0530 (US)

(72) Inventor: **Cho, Wing-Kee Philip**
Princeton, New Jersey 08540 (US)

(74) Representative: **Ritter, Stephen David et al**
Mathys & Squire
100 Gray's Inn Road
London WC1X 8AL (GB)

(54) Extended release oral dosage composition

(57) A compressed bilayer solid composition comprising (a) an immediate release first layer comprising an anti-allergic effective amount of desloratadine and at least one pharmaceutically acceptable excipient and (b)

a sustained release second layer comprising an effective amount of a nasal decongestant and a pharmaceutically acceptable sustained release agent wherein the composition contains less than about 2 % of desloratadine decomposition products is disclosed.

EP 1 110 543 A3



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 00 31 1443

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Y	EP 0 396 404 A (SCHERING CORPORATION) 7 November 1990 (1990-11-07)	1-8, 10-12, 15-18,21	A61K9/24 A61K31/4545
A	* the whole document *	9,13,14, 19,20	
D	* page 2, line 4 - line 6 * & US 5 100 675 A 31 March 1992 (1992-03-31)		
Y	WO 99 62516 A (SCHERING CORPORATION) 9 December 1999 (1999-12-09)	1,2,4-8, 10-12, 16-18,21	
	* the whole document *		
Y	EP 0 577 957 A (J. URIACH & CIA. S.A.) 12 January 1994 (1994-01-12)	1,3,15	
	* page 12, line 15 - line 24 *		
P,Y	WO 00 02560 A (SCHERING CORPORATION) 20 January 2000 (2000-01-20)	1,3,15	
	* the whole document *		
A	WO 98 34614 A (SEPRACOR, INC.) 13 August 1998 (1998-08-13)	1-21	TECHNICAL FIELDS SEARCHED (Int.Cl.7) A61K
	* page 10, line 26 - page 11, line 5 *		
A	EP 0 264 259 A (TAISHO PHARMACEUTICAL CO. LTD) 20 April 1988 (1988-04-20)	1-21	
	* the whole document *		
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 4 July 2001	Examiner Benz, K
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document			

EPO FORM 1503 03.92 (P04C01)

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 00 31 1443

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

04-07-2001

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 396404	A	07-11-1990	US 4990535 A	05-02-1991
			AT 101517 T	15-03-1994
			AU 628986 B	24-09-1992
			AU 5664890 A	29-11-1990
			CA 2054752 A,C	04-11-1990
			DE 69006628 D	24-03-1994
			DE 69006628 T	26-05-1994
			DK 396404 T	14-03-1994
			EP 0471009 A	19-02-1992
			ES 2062355 T	16-12-1994
			HK 184896 A	11-10-1996
			JP 6006536 B	26-01-1994
			JP 4501425 T	12-03-1992
			KR 9411246 B	03-12-1994
			MX 9203278 A	01-07-1992
			WO 9013295 A	15-11-1990
			US 5100675 A	31-03-1992
WO 9962516	A	09-12-1999	US 6132758 A	17-10-2000
			AU 4308599 A	20-12-1999
			EP 1082117 A	14-03-2001
			NL 1012191 C	04-01-2000
			NL 1012191 A	03-12-1999
EP 577957	A	12-01-1994	NO 20006079 A	30-11-2000
			ES 2042421 B	01-08-1994
			AT 124939 T	15-07-1995
			CA 2096318 A,C	23-11-1993
			DE 69300255 D	17-08-1995
			DE 69300255 T	04-01-1996
			DK 577957 T	04-12-1995
			ES 2076817 T	01-11-1995
			HK 1006169 A	12-02-1999
			JP 2730612 B	25-03-1998
			JP 6087856 A	29-03-1994
			KR 156518 B	16-11-1998
			MX 9302958 A	01-11-1993
			US 5407941 A	18-04-1995
			US 5476856 A	19-12-1995
WO 0002560	A	20-01-2000	AU 4953199 A	01-02-2000
			BR 9910449 A	02-01-2001
			EP 1073438 A	07-02-2001
			NO 20005485 A	09-03-2001
WO 9834614	A	13-08-1998	AU 6271998 A	26-08-1998

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 00 31 1443

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

04-07-2001

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9834614 A		BR 9806157 A	09-01-2001
		CN 1246794 T	08-03-2000
		CZ 9901194 A	11-08-1999
		EP 0969836 A	12-01-2000
		HU 0001527 A	28-04-2001
		NO 992157 A	04-05-1999
		PL 334232 A	14-02-2000
		SK 47299 A	13-03-2000
		ZA 9800977 A	30-07-1998
EP 264259 A	20-04-1988	JP 63096126 A	27-04-1988
		AT 59294 T	15-01-1991
		DE 3767114 D	07-02-1991
		US 4906647 A	06-03-1990

EPO FORM 10459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

Intrathecal Ketorolac Enhances Antinociception from Clonidine

Dawn R. Conklin, BA, and James C. Eisenach, MD

From the Department of Anesthesiology and Center for the Study of Pharmacologic Plasticity in the Presence of Pain, Wake Forest University School of Medicine, Winston-Salem, North Carolina

Although both α_2 -adrenergic agonists and cyclooxygenase inhibitors produce analgesia, their exact sites of action and interaction remain unclear. A previous report demonstrated a surprising inhibition of antinociception in rats from intrathecal clonidine by co-administered ketorolac. There are no other reports of interaction between these two classes of analgesics. We therefore reexamined this interaction, determining the effect of intrathecal clonidine and ketorolac alone and in combination in normal rats. Clonidine, but not ketorolac, produced antinociception to noxious hind paw

thermal stimulation. The addition of ketorolac significantly enhanced the effect of clonidine, indicating a synergistic interaction for analgesia. Although the reasons for the discrepancy between this and the previous report are unclear, these results are consistent with previous studies that indicate an antinociceptive action of intrathecal α_2 -adrenergic agonists in the normal condition, a lack of such effect for cyclooxygenase inhibitors, and positive reinforcing effects of these two systems when co-stimulated.

(Anesth Analg 2003;96:191-4)

The study of intrathecal application of drugs for the treatment of pain is important for two reasons. First, it is directly relevant to anesthesia practice in that the intrathecal space is often instrumented as part of perioperative, peripartum, or chronic pain care, and currently available intrathecal analgesics have significant shortcomings. Second, it provides important fundamental information regarding mechanisms of analgesic action and of pain transmission, which could guide pharmaceutical development of both intrathecal and systemic drug development. A good example of these rationales is examination of cyclooxygenase (COX) enzyme expression and inhibition in the spinal cord as it relates to pain treatment. COX is expressed in the normal spinal cord in small amounts, both isoforms COX-1 and COX-2, with the latter predominating (1). Indeed, the constitutive presence of COX-2 in the spinal cord has been suggested to underlie the early analgesic effect of COX inhibitors after surgery or other peripheral injury and at times before peripheral COX-2 expression is

increased. After peripheral injury, spinal COX-2 expression is greatly enhanced, leading to increased spinal release of prostaglandins with resultant increased substance P release and central sensitization (2). For this reason, spinally administered COX inhibitors produce analgesia after injury. We have recently completed preclinical toxicity screening of a COX inhibitor for intrathecal administration (JC Eisenach, unpublished observations) and, with the Food and Drug Administration, have begun clinical trials with this therapy.

It is becoming increasingly apparent that single drugs are unlikely to produce effective analgesia with minimal side effects, especially in the setting of chronic pain. For this reason, the study of drug interactions is relevant. Intrathecally administered COX inhibitors have been demonstrated to enhance analgesic effects of intrathecal opioids (3). Surprisingly, however, the other class of approved intraspinal analgesics, α_2 -adrenergic agonists, has been reported to be antagonized by the COX inhibitor ketorolac (4). Although there are complex interactions between noradrenergic and prostaglandin systems in the periphery, it is suggested that spinal prostaglandin production reduces norepinephrine release (5). There is no clear reason, based on known pharmacology, physiology, and anatomy of the α_2 -adrenergic and COX systems, why these two should interact in an antagonistic manner. The purpose of the current study was to test the

Supported, in part, by NIH grants GM35523 and NS41386.

Accepted for publication September 10, 2002.

Address correspondence and reprint requests to James C. Eisenach, MD, Department of Anesthesiology, Wake Forest University School of Medicine, Medical Center Blvd., Winston-Salem, NC 27157-1009. Address e-mail to eisenach@wfubmc.edu.

DOI: 10.1213/01.ANE.0000039319.43540.73

broadness of the previous observation of antagonism between intrathecal clonidine and ketorolac in normal animals in a different laboratory and using a slightly different noxious heat stimulus.

Methods

After Animal Care and Use Committee approval, adult male Sprague-Dawley rats (240–330 g; Harlan, Indianapolis, IN) were anesthetized with halothane. A catheter was inserted, as previously described, through a small nick in the cisterna magnum membrane into the intrathecal space and advanced 7.5 cm such that its tip lay in the lumbar intrathecal space. Rats recovered uneventfully, and proper catheter tip location was determined by appropriate bilateral lower-extremity motor block from an injection of 10 μ L of 2% lidocaine through the catheter on the day after preparation. After catheter implantation, rats were housed individually with a 12 h/12 h light/dark cycle and unlimited supply of water and food. Experiments occurred at least 6 days after surgery.

Antinociception was determined in response to noxious heat stimulus, which was applied using radiant heat from a focused high-intensity lamp. Rats were acclimated to the testing apparatus in which they were placed in Plexiglas containers on a glass surface maintained at 30°C. The lamp and lens were positioned under a hind paw and then activated. The lamp was automatically turned off when the rat rapidly raised its paw from the glass surface or at 30 s, a cutoff used to avoid tissue damage during periods of intense analgesia. Current to the lamp was adjusted between 5.0 and 5.3 A to obtain baseline withdrawal latencies of approximately 10 s and was thereafter not altered during the experiment.

After determination of baseline latency, rats received intrathecal injections in a 5- μ L volume, followed by an injection of 15 μ L of sterile saline to flush the catheter. Withdrawal latency was determined every 20 min for 80 min thereafter. The effect of clonidine was determined by the intrathecal injection of 1 and 10 μ g. We studied the maximum dose of ketorolac (50 μ g) obtainable in 10 μ L using the commercial preparation of ketorolac, Acular PF, to be used in clinical studies, alone and with 1 and 10 μ g of clonidine to test the interaction between these two. This formulation of ketorolac is in preservative-free saline. Drugs were purchased from Sigma Chemical Co (St Louis, MO) or Allergan (AcularPF; Palo Alto, CA) and were prepared in sterile normal saline. Spontaneous behavior (movement in the test apparatus and walking when placed unrestricted on a smooth surface) was also observed after drug treatment as a gross screen for sedative or motor effects. All injections were performed in an open-label manner.

Data were converted to percent maximum possible effect (%MPE, [observed latency – baseline latency]/

[30 s – baseline latency]) and are presented as %MPE over time or its integral (area under the %MPE/time curve) as mean \pm SE. Data were analyzed by one-way repeated-measures analysis of variance followed by the Dunnett test within individual dose groups to determine time course of effect and by two-way repeated-measures analysis of variance to determine differences between clonidine alone and clonidine plus ketorolac. $P < 0.05$ was considered significant.

Results

All rats recovered uneventfully from surgery, and lidocaine produced bilateral motor block in all cases. There were no prolonged effects observed from any of the tested drugs or doses, nor was gross motor block observed from any of the test drug injections.

Clonidine produced antinociception, as measured by increased latency to paw withdrawal from noxious heat, whereas ketorolac did not (Fig. 1). The addition of ketorolac to clonidine resulted in increased antinociception (Fig. 2).

Discussion

The interaction between clonidine and ketorolac in the current study was technically synergism because ketorolac had no effect alone but enhanced the effect of clonidine. These results therefore disagree with a previous report (4) indicating an antagonism of clonidine-induced antinociception by ketorolac. The reasons for this discrepancy are unclear, yet two factors would lead one to expect enhancement rather than antagonism by the combination of these drugs. First, α_2 -adrenergic agonists act by a different mechanism than COX inhibitors. α_2 -adrenergic receptors are both pre- and postsynaptically located relative to primary afferent terminals in the spinal cord (6). Stimulation of α_2 -adrenergic receptors by agonist exposure *in vitro* and *in vivo* reduces release of excitatory neurotransmitters from noxious stimuli in the spinal cord, including substance P (7), calcitonin gene-related peptide (8), and glutamate (9). Additionally, stimulation of α_2 -adrenergic receptors hyperpolarizes dorsal horn neurons with rostral projections (10), indicating direct postsynaptic effects. α_2 -adrenergic receptors are coupled primarily to Gi/Go G proteins and reduce adenylyl cyclase activity as well as increasing resting K^+ conductance (4,11). In contrast, COX inhibitors prevent synthesis of sensitizing prostaglandins, primarily prostaglandin E2 (PGE2), in the spinal cord. Prostaglandins act both pre- (2) and postsynaptically (12) to enhance excitatory neurotransmission in the spinal cord, reflecting both exaggerated glutamate, calcitonin gene-related peptide (CGRP), and substance P release and exaggerated response to their release.




Figure 1. Antinociception, measured as percent maximum possible effect (%MPE) after intrathecal injection at time 0 of ketorolac 50 µg (solid squares) or clonidine 1 µg (open circles) or 10 µg (open squares).

Spinally produced PGE2 acts at several receptor subtypes. EP1 antagonists block allodynia from acute blockade of γ -aminobutyric acid receptors with intrathecal bicuculline (13) and from partial sciatic nerve section (14) or sciatic nerve constriction injury (15). Mice lacking the EP1 receptor gene exhibit decreased response to intraperitoneal acetic acid (16) and decreased allodynia from intrathecal PGE2 (17). There is also evidence for other subtypes in pain transmission: EP2 antagonists selectively block postsynaptic excitation in dorsal horn neurons induced by PGE2 (12), and mice lacking the EP3 receptor show decreased thermal hyperalgesia from intrathecal PGE2 (17). In most cases, these receptors are coupled to different second messenger systems than α 2-adrenergic receptors, so one would expect enhancement by combining these drugs that act via different mechanisms.

Second, spinally released norepinephrine stimulates PGE2 synthesis by an action on α 1-adrenoceptors (5), and this PGE2 synthesis is thought to reduce the net antinociceptive effect of norepinephrine. Clonidine, although selective for α 2-adrenergic receptors, has some α 1-adrenergic agonist activity at large concentrations (18), such as might occur after intrathecal injections. One would expect that this spillover into α 1-adrenergic receptor stimulation by clonidine would diminish its net antinociception and that this reduction would be abolished by the prevention of PGE2 synthesis by ketorolac.

It is conceivable that the difference between the current report (synergy between ketorolac and clonidine) and the previous report (antagonism of clonidine by ketorolac) (4) could also reflect the different proportions at which they were mixed (50:1 or 5:1 in the current report compared with 1:1 in the




Figure 2. Antinociception, measured as percent maximum possible effect (%MPE) after intrathecal injection of clonidine (open circles) alone or clonidine plus ketorolac 50 µg (closed circles). * $P < 0.05$ compared with clonidine alone.

previous report). Drug interactions vary with ratio of their combination, not only quantitatively, but also qualitatively, and there are other examples of drugs that interact with antagonism at one ratio but with additivity or synergy at another ratio (19). This explanation would suggest that several ratios of these drugs be investigated in humans rather than focus on a single ratio.

The lack of efficacy of intrathecal ketorolac alone in the current study was not surprising given the lack of efficacy of intrathecal COX inhibitors to tail-flick, hot-plate, or paw withdrawal to noxious heat (20). In contrast, intrathecal COX inhibitors are effective after inflammation (21) or peripheral nerve injury models of mechanical hypersensitivity and neuropathic pain (22). Because intrathecally administered α 2-adrenergic agonists increase in potency and efficacy in such models (23) and epidural clonidine effectively treats patients with neuropathic pain (24), interactions between α 2-adrenergic agonists and COX inhibitors might be even more positive in hypersensitivity states.

In summary, intrathecal ketorolac lacks efficacy in normal rats subjected to acute, noxious heat stimuli but enhances the effect of intrathecal clonidine. These

data refute a previous report and provide a rationale for clinical study of the combination of these drugs.

References

1. Maihöfner C, Tegeder I, Eichenhofer C, et al. Localization and regulation of cyclo-oxygenase-1 and -2 and neuronal nitric oxide synthase in mouse spinal cord. *Neuroscience* 2000;101:1093-1108.
2. Malmberg AB, Yaksh TL. Capsaicin-evoked prostaglandin E₂ release in spinal cord slices: relative effect of cyclooxygenase inhibitors. *Eur J Pharmacol* 1994;271:293-9.
3. Malmberg AB, Yaksh TL. Pharmacology of the spinal action of ketorolac, morphine, ST-91, U50488H, and L-PIA on the formalin test and an isobolographic analysis of the NSAID interaction. *Anesthesiology* 1993;79:270-81.
4. Tejwani GA, Rattan AK. Antagonism of antinociception produced by intrathecal clonidine by ketorolac in the rat: the role of the opioid system. *Anesth Analg* 2000;90:1152-6.
5. Taiwo YO, Levine JD. Prostaglandins inhibit endogenous pain control mechanisms by blocking transmission at spinal noradrenergic synapses. *J Neurosci* 1988;8:1346-9.
6. Howe JR, Yaksh TL, Go VL. The effect of unilateral dorsal root ganglionectomies or ventral rhizotomies on α_2 -adrenoceptor binding to, and the substance p, enkephalin, and neurotensin content of, the cat lumbar spinal cord. *Neuroscience* 1987;21:385-94.
7. Kuraishi Y, Hirota N, Sato Y, et al. Noradrenergic inhibition of the release of substance P from the primary afferents in the rabbit spinal dorsal horn. *Brain Res* 1985;359:177-82.
8. Bourgoin S, Pohl M, Mauborgne A, et al. Monoaminergic control of the release of calcitonin gene-related peptide- and substance P-like materials from rat spinal cord slices. *Neuropharmacology* 1993;32:633-40.
9. Kamisaki Y, Hamada T, Maeda K, et al. Presynaptic α_2 adrenoceptors inhibit glutamate release from rat spinal cord synaptosomes. *J Neurochem* 1993;60:522-6.
10. North RA, Yoshimura M. The actions of noradrenaline on neurones of the rat substantia gelatinosa in vitro. *J Physiol* 1984;349:43-55.
11. Uhlén S, Wikberg JES. Inhibition of cyclic AMP production by α_2 -adrenoceptor stimulation in the guinea-pig spinal cord slices. *Pharmacol Toxicol* 1988;63:178-82.
12. Baba H, Kohno T, Moore KA, Woolf CJ. Direct activation of rat spinal dorsal horn neurons by prostaglandin E₂. *J Neurosci* 2001;21:1750-6.
13. Zhang ZZ, Hefferan MP, Loomis CW. Topical bicuculline to the rat spinal cord induces highly localized allodynia that is mediated by spinal prostaglandins. *Pain* 2001;92:351-61.
14. Syriatowicz J-F, Hu D, Walker JS, Tracey DJ. Hyperalgesia due to nerve injury: role of prostaglandins. *Neuroscience* 1999;94:587-94.
15. Kawahara H, Sakamoto A, Takeda S, et al. A prostaglandin e(2) receptor subtype ep(1) receptor antagonist (ono- 8711) reduces hyperalgesia, allodynia, and c-fos gene expression in rats with chronic nerve constriction. *Anesth Analg* 2001;93:1012-7.
16. Stock JL, Shinjo K, Burkhardt J, et al. The prostaglandin E₂ EP1 receptor mediates pain perception and regulates blood pressure. *J Clin Invest* 2001;107:325-31.
17. Nakano H, Kobayashi T, Sugimoto Y, et al. Characterization of EP receptor subtypes responsible for prostaglandin E₂-induced pain responses by use of EP₁ and EP₃ receptor knockout mice. *Br J Pharmacol* 2001;133:438-44.
18. Kobinger W, Pichler L. α_1/α_2 Selectivity ratio in a series of agonists and their relation to pre/postsynaptic activity ratios. *Eur J Pharmacol* 1983;91:129-33.
19. Tallarida RJ, Porreca F, Cowan A. Statistical analysis of drug-drug and site-site interactions with isobolograms. *Life Sci* 1989;45:947-61.
20. McCormack K. Non-steroidal anti-inflammatory drugs and spinal nociceptive processing. *Pain* 1994;59:9-43.
21. Yaksh TL, Dirig DM, Conway CM, et al. The acute antihyperalgesic action of nonsteroidal, anti-inflammatory drugs and release of spinal prostaglandin E₂ is mediated by the inhibition of constitutive spinal cyclooxygenase-2 (COX-2) but not COX-1. *J Neurosci* 2001;21:5847-53.
22. Zhao Z, Chen SR, Eisenach JC, et al. Spinal cyclooxygenase-2 is involved in development of allodynia after nerve injury in rats. *Neuroscience* 2000;97:743-8.
23. Puke MJC, Wiesenfeld-Hallin Z. The differential effects of morphine and the α_2 -adrenoceptor agonists clonidine and dexmedetomidine on the prevention and treatment of experimental neuropathic pain. *Anesth Analg* 1993;77:104-9.
24. Eisenach JC, DuPen S, Dubois M, et al. Epidural clonidine analgesia for intractable cancer pain. *Pain* 1995;61:391-9.